Hodak: Million-dollar blindness gene therapy only marginally slows vision loss for 3%
Max Hodak · Can The Brain Merge With Artificial Intelligence? — With Max Hodak · Dec 12, 2025 · at 5:51
Max Hodak, CEO of Science, contrasts conventional molecular drug discovery approaches for blindness with neural engineering implants.
0:00 / 0:18exact quote · 18.5s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“There's a gene therapy that's on market that costs almost a million dollars a patient, and it doesn't, first of all, it's only applicable for, like, three percent of patients that have this type of blindness, and it also just doesn't really work. Like, it very marginally slows the rate of descent for a small number of patients.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Max Hodak
Hodak: AI internal representations empirically converge with brain representations
“When you look inside these AI models, you see These mathematical objects that look a lot like what you see in the brain in neuroscience. Like, the representations are converging, and this is an empirical finding.”
Humanity could meaningfully merge consciousness with machines by 2035, Hodak predicts
“Probably not next year, but I think within the next decade. Wow. It's very possible that this stuff is going to get figured out in a meaningful way. I think like, 2035 will be a very, very different world than 2025.”
Hodak: Next-gen BCIs could empower stroke patients within five years
“When I think about the next generation BCI technologies that are on the horizon that are getting developed, I think it's very possible that in the next four or five years, there'll be some patients that maybe had a stroke, maybe had Some other injury, who, you…”
Hodak: Current AI progress is still not priced in
“I think that the progress that's happening in AI is, is much better known than any of this, but it's still not priced in.”
Hodak: Neural engineering produces therapeutic effect sizes unseen in conventional medicine
“One of the reasons that I like the neural engineering approach is it produces these very large effect sizes. Like, cochlear implants, really, if you are deaf due to sensorineural hearing loss, they really work. Or if you've ever seen a video of a Parkinson's p…”
Hodak: Science's retinal implant restored reading in macular degeneration patients
“So our lead program at Science is a retinal prosthesis. It's a chip that's implanted in the back of the eye. We just, we finished a major clinical trial last summer in age-related macular degeneration where patients that are unable to recognize faces have been…”